Patents by Inventor Jorge Laborda

Jorge Laborda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEDF-R RECEPTOR AND USES
    Publication number: 20090162363
    Abstract: A pigment epithelium derived factor (“PEDF”) receptor designated PEDF-R and PEDF-R encoding nucleic acid and amino acid sequences. Wild type PEDF-R, PEDF-R variants, soluble PEDF-R variants, chimeric PEDF-R, and antibodies which bind to the PEDF-R (including agonist and neutralizing antibodies), as well as various uses for these molecules are described. Assay systems for detecting ligands to PEDF-R, systems for studying the physiological role of PEDF-R and its ligands, diagnostic techniques for identifying PEDF-related conditions, therapeutic techniques for the treatment of PEDF-related and PEDF-R related conditions, and methods for identifying molecules homologous to PEDF-R.
    Type: Application
    Filed: August 5, 2004
    Publication date: June 25, 2009
    Inventors: Sofia Patricia Becerra, Luigi Notari, Jorge Laborda, Julio Escribano-Martinez
  • Delta-like gene expressed in neuroendocrine tumors
    Patent number: 5644031
    Abstract: A polynucleotide molecule dlk is expressed in neuroendocrine tumors, including small cell lung carcinoma. A Dlk polypeptide encoded by dlk polynucleotide molecule can be used in detecting the existence of a primary or secondary neuroendocrine tumor. Monoclonal antibodies are produced against Dlk which are useful for detection and therapy of a neuroendocrine tumor.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 1, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Jorge Laborda
  • Delta-like gene expressed in neuroendocrine tumors
    Patent number: 5580738
    Abstract: A polynucleotide molecule dlk is expressed in neuroendocrine tumors, including small cell lung carcinoma. A Dlk polypeptide encoded by dlk polynucleotide molecule can be used in detecting the existence of a primary or secondary neuroendocrine tumor. Monoclonal antibodies are produced against Dlk which are useful for detection and therapy of a neuroendocrine tumor.
    Type: Grant
    Filed: February 1, 1996
    Date of Patent: December 3, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Jorge Laborda